Optimizing Medication Use to Support Functional Recovery

Abstract

Optimizing medication use is fundamental to enhancing functional recovery in patients with acute and chronic health conditions. Polypharmacy, inappropriate prescribing, and undertreatment can hinder rehabilitation and prolong disability. This review synthesizes current evidence on the impact of medication management on functional outcomes, examines mechanisms influencing recovery, and discusses guideline-based strategies for clinicians. Emphasis is placed on individualized pharmacotherapy, deprescribing when appropriate, and integrating pharmacological and non-pharmacological interventions to maximize patient independence and quality of life.

Introduction

Functional recovery defined as the restoration of a patient’s ability to perform activities of daily living (ADLs) is a primary goal in the management of many acute and chronic illnesses, including stroke, musculoskeletal injuries, heart failure, and geriatric syndromes. Medications play a dual role: they can significantly aid recovery but also pose risks for functional decline due to adverse drug events and interactions. Therefore, optimizing medication use is essential for promoting recovery and minimizing harm. This article provides a comprehensive review for clinicians, examining evidence-based strategies, clinical considerations, and recent advances in optimizing pharmacotherapy to support functional outcomes.

Epidemiology / Disease Burden

The burden of functional impairment is substantial, especially among older adults and individuals with multimorbidity. Epidemiological studies indicate that up to 30% of older adults experience functional decline during hospitalization, with medication-related problems contributing significantly. Polypharmacy affects approximately 40-50% of older adults, increasing the risk of falls, delirium, and prolonged disability. Furthermore, medication mismanagement accounts for a considerable proportion of preventable hospital readmissions and institutionalization, highlighting the urgent need for optimized pharmacotherapy in both acute and chronic care settings.

Pathophysiology

The pathophysiological basis for medication-related functional decline is multifactorial. Central nervous system (CNS) depressants, anticholinergics, and sedative-hypnotics can impair cognition, mobility, and balance, leading to increased falls and disability. Cardiovascular medications may cause orthostatic hypotension, while hypoglycemic agents can induce episodes of delirium and weakness in vulnerable populations. Conversely, underutilization of essential medications (e.g., statins post-cardiovascular events, anticoagulants in atrial fibrillation) can impede recovery and increase complication rates. Understanding pharmacokinetics and pharmacodynamics in patients with altered physiology (e.g., renal impairment, frailty) is crucial for optimizing drug selection and dosing to support recovery.

Risk Factors

Risk factors for medication-related functional impairment include advanced age, multimorbidity, polypharmacy (defined as the use of five or more medications), cognitive impairment, renal or hepatic dysfunction, and transitions of care (e.g., hospital discharge). Patients with low health literacy or inadequate social support are also at increased risk. Clinical vigilance is necessary when prescribing medications with high anticholinergic burden, potential for drug-drug interactions, or a narrow therapeutic index.

Clinical Features

Clinically, medication-related functional impairment may present as unexplained falls, new-onset confusion or delirium, decline in mobility, urinary incontinence, or worsening of pre-existing disability. Adverse drug reactions (ADRs) are often underrecognized in older adults, as they may present atypically or mimic symptoms of underlying disease. Early identification of such features through comprehensive medication review and ongoing monitoring is essential in at-risk populations.

Diagnosis

Diagnosis of medication-related functional decline involves a systematic approach, including detailed medication reconciliation, assessment of recent medication changes, and evaluation of temporal relationships between drug initiation or dose changes and onset of symptoms. Functional assessment tools such as the Barthel Index, Katz ADL scale, and Timed Up and Go test can aid in quantifying functional status and monitoring recovery. Collaboration with pharmacists and use of clinical decision support systems are effective in identifying potential drug-related problems.

Treatment & Management

Optimizing pharmacotherapy requires a patient-centered approach, balancing the benefits and risks of each medication. Key strategies include regular medication review, deprescribing inappropriate or unnecessary drugs, and substituting safer alternatives where possible. Integrating non-pharmacological interventions such as physical therapy, occupational therapy, and nutritional support is critical for holistic recovery. Multidisciplinary team involvement, including input from geriatricians, rehabilitation specialists, and pharmacists, enhances the safety and efficacy of medication regimens.

Recent Advances / Emerging Therapies

Recent advances include the development of evidence-based deprescribing guidelines, computerized medication management tools, and risk prediction models for ADRs. Pharmacogenomics is emerging as a tool to guide personalized therapy, minimizing side effects and maximizing functional benefits. There is growing evidence for the use of comprehensive geriatric assessment (CGA) in optimizing medication regimens and improving functional outcomes. Newer agents with improved safety profiles, such as SGLT2 inhibitors in heart failure, have shown functional benefits beyond disease control in select populations.

Guideline Recommendations

Major guidelines from organizations such as the American Geriatrics Society and NICE recommend regular medication reconciliation, use of validated screening tools to identify high-risk medications, and individualized deprescribing protocols. The Beers Criteria and STOPP/START criteria provide specific recommendations to avoid potentially inappropriate medications and ensure essential therapies are not omitted. Shared decision-making with patients and caregivers is emphasized to align pharmacotherapy with individual goals of care and functional priorities.

Conclusion

Optimizing medication use is a cornerstone of functional recovery in clinical practice. By employing evidence-based strategies ranging from comprehensive medication review to tailored deprescribing clinicians can significantly improve patient outcomes, reduce adverse events, and promote independence. Ongoing research and innovation in pharmacotherapy, decision support, and personalized medicine will continue to enhance the ability of healthcare professionals to support functional recovery across diverse patient populations.